ReGen Therapeutics Plc. (ReGen), London, U.K., has entered into an exclusive license agreement with Metagenics, Inc., San Clemente, CA, for the commercialization of ReGen’s Colostrinin as a human nutraceutical in North America. The agreement is conditional on, amongst other things, satisfactory completion of toxicology testing on Colostrinin and of due diligence by Metagenics on the Colostrinin man ufacturing facilities. Subject to satisfactory completion of the conditions of the agreement and requisite U.S. regulatory filings, ReGen currently anticipates launch of a human nutraceutical containing Colostrinin during the first half of 2007.
In other news, Metagenics has teamed up with Carotech Inc., Edison, NJ, for the commercialization of Tocomin SupraBio, a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex for the healthcare practitioner channel. Carotech will collaborate with Metagenics to formulate new and unique products with Tocomin SupraBio, as well as establish the best commercialization strategy for introducing this novel tocotrienol complex to the healthcare practitioner channel in North America.